Aurolab房水引流装置经睫状体扁平部植入治疗难治性青光眼的中期结局
该回顾性研究纳入63眼难治性青光眼,经睫状体扁平部植入Aurolab房水引流装置,平均随访19.7个月,眼压从36.6 mmHg显著下降至2年时17.2 mmHg,2年累积失败概率47%,玻璃体阻塞管口发生率最高8%,提示该手术对难治性青光眼控压有效。
要点
- 经睫状体扁平部植入AADI可显著降低难治性青光眼眼压,2年眼压降幅约53%。
- 2年累积失败概率达47%,中期失败风险较高,需长期随访。
- 玻璃体阻塞管口在随访中发生率最高8%,为常见并发症。
核心结论
- 经睫状体扁平部植入Aurolab房水引流装置是控制难治性青光眼眼压的有效手术方式。
研究设计与样本
- 回顾性病例系列研究,纳入2014年6月至2018年6月期间接受经睫状体扁平部AADI植入的难治性青光眼患者,最少随访6个月,共63眼63例,平均年龄36.1±20.6岁,平均随访19.7±15.7个月。
主要发现
- 玻璃体视网膜术后青光眼是最常见病因(22眼,35%)。
- 平均眼压从基线36.6±10.7 mmHg降至6个月15.7±8.2 mmHg(降幅57.1%)、1年15.02±7.3 mmHg(降幅60%)和2年17.2±8.5 mmHg(降幅53%)。
- Kaplan-Meier估计累积失败概率为6个月8%(95%CI 4.3%–22.4%)、1年23%(95%CI 12.8%–38.6%)、18个月30%(95%CI 17.4%–45.9%)和2年47%(95%CI 13.4%–64.9%)。
- 随访中玻璃体阻塞管口发生率最高达8%。
关键数值与推荐
- 完全成功定义为眼压≥5且≤18 mmHg或眼压较基线下降>30%且不使用抗青光眼药物。
- 条件成功定义为需要额外使用抗青光眼药物。
临床怎么用
- 对于难治性青光眼,尤其是玻璃体视网膜术后患者,可考虑经睫状体扁平部植入AADI以控制眼压。
- 术后需长期监测眼压及管口阻塞等并发症,因中期失败率较高。
局限性
- 回顾性研究设计,样本量有限(63眼),随访时间不一致,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the safety and efficacy of parsplana tube insertion of Aurolab aqueous drainage implant(AADI) in patients with refractory glaucoma. METHODS: Charts of patients with refractory glaucoma who underwent AADI via the parsplana route between June 2014 and June 2018with a minimum follow-up of 6 months were retrospectively reviewed. Success was defined as complete when the intraocular pressure (IOP) was ≥5 and18 mmHg or IOP reduction was >30%from baseline without antiglaucoma medication (AGM) andas qualified if requiring additional AGMs. RESULTS: The study included 63 eyes of 63 patients with a mean age of 36.1±20.6 years and a mean follow-up of 19.7±15.7 months. Glaucoma postvitreoretinal surgery was the the most common aetiology (22 eyes, 35%). The mean IOP reduced from 36.6±10.7 mmHg to15.7±8.2 (57.1%), 15.02±7.3 (60%) and 17.2±8.5 mmHg (53%)at 6 months and 1 and 2 years, respectively. Kaplan-Meier estimates showed that the cumulative probabilities of failure were 8% (95% CI4.3% to 22.4%) at 6 months, 23% (95%CI12.8% to 38.6%) at 1 year, 30% (95%CI17.4% to 45.9%) at 18 months and 47% (95% CI13.4% to 64.9%) at the 2 years time points.Vitreous blocking tube tip was noted up to 8% of eyes on follow-up. CONCLUSION: Pars plana AADI insertion is a useful procedure for the control of IOP in patients with refractory glaucoma.
引用
- Babu N, Baliga G, Wijesinghe HK, et al. Intermediate-term outcomes of pars plana tube insertion of Aurolab aqueous drainage implant for refractory glaucoma. Br J Ophthalmol. 2019. PMID: 31796429. doi:10.1136/bjophthalmol-2019-314639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。